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Abstract: Health care in Sub-Saharan Africa is being challenged by a double burden of disease
as lifestyle diseases common in the developed world, such as stroke and atrial fibrillation (AF),
increase, while, simultaneously, health issues of the developing world in terms of communicable disease persist. The prevalence of AF is lower in Africa than in the developed world but
is expected to increase significantly over the next few decades. Patients with AF in Africa tend
to be younger and have a higher prevalence of rheumatic valvular heart disease than patients
with AF in other regions. Permanent AF is the most prevalent type of AF in Africa, possibly
due to the lower use of rhythm control strategies than in the developed world. Mortality rates
of patients with AF in Africa are high, due largely to poor health care access and suboptimal
therapy. The risk of stroke in AF, which is moderate to high in Africans as in the developed
world, contributes to the high mortality rate. Patients with AF in Africa are often undertreated
with antithrombotics, as cost and access to monitoring are major barriers. Vitamin K antagonists,
including warfarin, are the most commonly available oral anticoagulants, but regular monitoring
can be challenging, especially for patients in remote areas. Several non-vitamin K antagonist
oral anticoagulants (NOACs) have been approved for use in countries across Sub-Saharan Africa
and have the potential to reduce stroke burden. The higher cost of newer agents may be offset by
the reduced need for regular monitoring, fixed dosing, and lower risk of intracranial bleeding;
NOACs could provide a treatment option for patients in remote areas with limited access to
regular monitoring. However, NOACs are not indicated in valvular AF. More work is needed to
increase understanding of the epidemiology of AF and stroke, as well as to improve management
strategies to reduce the burden of cardiovascular disease predicted for Africa.
Keywords: stroke, real-world treatment, treatment guidelines, barriers to care, non-vitamin K
antagonist oral anticoagulants
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Economic and social changes in Sub-Saharan Africa are producing increased prosperity, but unfortunately, they are also driving an epidemiological transition to a double
burden of disease in the region.1,2 Health care systems in the developing world are challenged both by significant public health issues related to communicable disease and,
increasingly, by a rising prevalence of noncommunicable lifestyle diseases, including
obesity, tobacco addiction, hypertension, diabetes, and cardiovascular disease.2 Atrial
fibrillation (AF) is the most common sustained cardiac arrhythmia in the developed
world, and its prevalence in Africa is expected to grow as risk factors for AF, including an aging population, increase in this region.3,4 Additionally, the large incidence
of undertreated streptococcal infections in Africa contributes to the high burden of
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valvular AF associated with rheumatic heart disease.5,6 The
largest relative increase in cardiovascular disease burden
between 1990 and 2010 in Sub-Saharan Africa was in AF.7
It is estimated that by 2050, the prevalence of AF in Africa
will be greater than in any other region of the world.8
The impact of AF on patients in Africa is not well
characterized. However, it is important to increase awareness
and understanding of AF in Africa for the future, as AF is a
significant risk factor for stroke. Compared with stroke from
other causes, a stroke associated with AF tends to be more
disabling and carries a higher risk of death.9–11 Although the
prevalence of stroke in Sub-Saharan Africa remains lower
than in many developed countries, the burden of disease
is high, with a high incidence of stroke-related mortality.12
The leading cardiovascular cause of death and disability in
2010 in Sub-Saharan Africa was stroke.7 Even in developed
regions where high-quality health care is readily accessible, patients with AF are undertreated with anticoagulant
therapy;13,14 similarly, data indicate that patients with AF in
Africa receive suboptimal antithrombotic treatment to reduce
their risk of stroke.2,15 Additional attention and resources are
needed for prevention and treatment of AF and its associated
complications on the African continent and the developing
world in general.

Epidemiology
Data on the prevalence and incidence of AF in Africa are
sparse, but several small studies have been published since
2010. A systematic review of AF epidemiology in developing
regions suggested that the prevalence of AF in Africa currently is lower than in other regions studied.16 The reported
prevalence of AF varies somewhat among studies and is
expected to differ between hospital-based studies and in the
general population, due at least in part to the patient selection
in some hospitals being driven by factors such as affordability and health care-seeking behavior. In a hospital-based
study in South Africa, 4.6% of cardiology patients had AF,
indicating an estimated prevalence of 5.6 cases per 100,000
population per year.2 Similarly, in a retrospective chart
review (N=3,908) at a cardiology institute in Ivory Coast, the
prevalence of AF was 5.5% among patients admitted to the
hospital over a 10-year period.17 In a retrospective study at a
hospital in Senegal, the overall prevalence of AF was 5.4%
and accounted for 66% of heart rhythm disorders.18 A lower
prevalence rate of AF was reported in a Kenyan study in
which the prevalence of AF and flutter in a tertiary referral
hospital among medical patients was 0.7% (162/22,144);
15% of these patients presented with a thromboembolic event
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(of patients with a thromboembolic event, 53% were of Asian
or Caucasian origin).19 Among elderly residents ($70 years
old) in a rural community in Tanzania, the crude prevalence
rate of AF was strikingly low, at 0.7%.20 This estimate is much
lower than the AF rates in elderly populations in the US or
the European Union, where approximately 5% of people
aged $65 years and 10% of people aged $80 years have
been diagnosed with AF.21,22 The low rate of AF in African
populations reported in some studies may be related to health
care-seeking behavior and the fact that many patients do not
have ready access to good health care. With increased access,
it is likely that a higher prevalence of AF will be observed
across Sub-Saharan Africa.
With regard to prevalence of AF among the African population, it is notable that the prevalence and incidence of AF
in the US is lower among African American men and women
than in white men and women, even though risk factors for
AF are more common among African Americans.23,24 These
observations suggest that genetic factors may be contributing to a lower prevalence of AF in native Africans, but at
this time, the contribution of genetic variants to a lower AF
susceptibility in this population remains uncertain. It will be
interesting to study whether environmental factors associated
with increased urbanization and life expectancy in some parts
of Sub-Saharan Africa will result, as predicted, in a higher
AF burden in future years.
AF is independently associated with an increased risk of
death.3 In the Framingham Heart Study, AF was associated
with a 1.5- to 1.9-fold increase in mortality over 40 years of
follow-up.25 In a study among a predominantly white population in Olmsted County, MN, USA (mean age 73±14 years),
the Kaplan–Meier estimates of survival at 4 months and 1 year
after first AF diagnosis were 83% (95% confidence interval
[CI]: 82%–85%) and 77% (95% CI: 76%–78%).26 Notably,
among patients aged .70 years with electrocardiogramconfirmed AF in rural Tanzania, the 1-year mortality rate
was extremely high (50.0% in men and 66.6% in women).20
Likewise, among an urban population with AF in Cameroon,
the 1-year mortality rate after diagnosis was high (29.5%).15
The lower reported prevalence of AF in Africa may also be
related to higher mortality in patients with AF in that region,
due to underdiagnosis and undertreatment in settings with
limited health care resources.27
The pattern of AF can be classified as paroxysmal, persistent, or permanent. Paroxysmal AF is self-terminating,
usually within 48 hours, but may continue for up to 7 days.
Persistent AF is present when an AF episode either lasts longer
than 7 days or requires termination by cardioversion, either
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with drugs or by direct current cardioversion. Permanent
AF is said to exist when the presence of the arrhythmia is
accepted by the patient and physician. Notably, paroxysmal
AF carries the same risk of stroke as permanent or persistent
AF.11 With regard to these AF subtypes, permanent AF is the
most prevalent type of AF among African individuals. In a
prospective study of AF patients in Cameroon, the prevalence
of paroxysmal, persistent, and permanent AF was 23%, 22%,
and 56%, respectively.15 In a private, urban referral teaching
hospital in East Africa, the distribution was paroxysmal
AF 40%, persistent AF 13.5%, and permanent AF 40%
(the remainder had incomplete follow-up data).19 African
patients may progress more rapidly to permanent AF due to
the reduced likelihood of detection when AF is paroxysmal
and due to the less-frequent use of rhythm control therapies
to restore and maintain sinus rhythm. Although some studies
suggest that the permanent form of AF may be less common
in the US and Europe (estimated prevalence of 30%–40%),
other studies demonstrate that worldwide, permanent AF
occurs in approximately 50% of patients, and the paroxysmal
and persistent forms of AF occur in 25% each.28–31
Patients with AF have a greater risk of stroke than the
general population; however, the stroke risk is heterogeneous,
modulated significantly by patient comorbidities. A number of
risk stratification measures have been developed to predict the
risk of stroke among patients with AF. One of the most commonly used and well-validated methods is the CHADS2 score,
which stratifies patients by history of Congestive heart failure,
Hypertension, Age $75 years, Diabetes (one point for each),
and Stroke or transient ischemic attack (two points).32 Patients
with a CHADS2 score of zero are considered to be at lower
risk of stroke; those with a score of one are considered to be
at moderate risk, while those with a score $2 are considered
to be at high risk.33,34 In a South African hospital-based study,
the mean overall CHADS2 score of patients with AF (in 195
nonrheumatic cases) was 1.5±0.9.2 In a study from a cardiac
referral center in Cameroon, the mean CHADS2 score was
1.9±0.1, and 92% of patients had a CHADS2 score $1.15 In a
study based at the Cardiology Institute in Abidjan, Ivory Coast,
47% of patients had a CHADS2 score of one or two, while 18%
had a CHADS2 score $3.17 In the Kenya series mentioned previously, 65% of patients had a CHADS2 score .2.19 Similarly,
in a European cohort, 20% of patients had a CHADS2 score of
zero, 62% had a score of one or two, and 18% had a score $3.33
Thus, similar to other regions of the world, most patients with
AF in Africa are at moderate-to-high risk of stroke.
The CHA2DS2–VASc point scoring system is a modification of CHADS2, which includes a larger number of risk factors
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(female sex, 65–74 years of age, and vascular disease) and has
a broader score range (zero to nine). CHA2DS2–VASc (rather
than CHADS2) has been given a Class I recommendation to
assess stroke risk according to the 2012 European Society
of Cardiology (ESC) and the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society
(AHA/ACC/HRS) AF Guidelines.35,36 CHA2DS2–VASc scores
of zero and one are associated with adjusted stroke rates (percentage per year) of 0% and 1.3%, respectively, and a score of
nine has a stroke rate of 15.2%.36 Notably in several studies,
the CHA2DS2–VASc system discriminated stroke risk better
among subjects with a baseline CHADS2 score of zero to one
and defined anticoagulation recommendations more clearly
than the CHADS2 score.35 However, because the CHA2DS2–
VASc scoring system has not been validated in the native
African population, its utility in this setting currently remains
uncertain and may be limited pending its validation.

Risk factors for AF
Valvular AF
AF may be divided into two categories: valvular AF and
nonvalvular AF (NVAF). Valvular AF can be defined as AF
that occurs in association with a prosthetic heart valve, valve
repair, or rheumatic valvular heart disease (predominantly
mitral stenosis caused by prior streptococcal infection).36
Rheumatic heart disease associated with valvular AF is much
more common in Africa than in North America or Europe.2
Among the regions enrolled in Randomized Evaluation of
Long-Term Anticoagulation Therapy (RE-LY) AF, a global
prospective registry that enrolled patients presenting to an
emergency department with AF, rheumatic heart disease was
present in 22% of African patients vs 2% of North American
patients (Table 1). As a consequence of the higher prevalence
Table 1 Selected risk factors for AF in African patients compared
with the global population enrolled in a prospective registry of
emergency department patients presenting with AF
Number of patients with AF
Age, years, mean (SD)
Hypertension, %
Previous stroke or TIA, %
Heart failure, %
Diabetes mellitus, %
Rheumatic heart disease, %
CHADS2 score, mean

Africa

Overall

1,137
57* (19)
54*
14
64*
14*
22*
1.8

15,400
66 (15)
62
14
35
22
2
1.8

Notes: *Significantly different from the rest of the world (P,0.005). Data from
Walker et al.37
Abbreviations: AF, atrial fibrillation; CHADS2, Congestive heart failure, Hyper
tension, Age $75 years, and Diabetes (one point each), Stroke or transient ischemic
attack (two points); SD, standard deviation; TIA, transient ischemic attack.
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of rheumatic heart disease, AF may affect people in Africa
at a younger age than in the US or Europe. In RE-LY AF,
Africa had the youngest median age of patients with AF
(57.2 years, standard deviation [SD]: 18.8 for African patients
vs 70.1 years, SD: 13.4 for North American patients).37

NVAF
Risk factors associated with NVAF include older age, hypertension, diabetes, and heart disease.36 Several AF risk factors
are prevalent among patients with AF in Africa. In a prospective study of AF patients in Cameroon, underlying cardiac disorders, including hypertensive heart disease (48%), valvular
heart disease (VHD; 26%), dilated cardiomyopathy (16%),
and coronary artery disease (6%), were present in 156/172
patients (91%).15 Similarly, a retrospective study of patients
with AF in a teaching hospital in Kenya reported associated
comorbidities, including hypertension (68%), heart failure
(38%), diabetes mellitus (33%), and valvular abnormalities
(12%).19 Among participants in the RE-LY AF registry, some
risk factors for AF (older age, hypertension, and diabetes)
were lower among Africans than in other regions of the world,
but heart failure was much more common in Africans with
AF (Table 1).37 The incidence of NVAF in Africa is likely
to increase as rates of hypertension, diabetes, and other risk
factors increase and the population ages.2

Burden of AF and stroke
AF is associated with an increased risk of stroke. Reported
stroke prevalence varies throughout Africa, depending on the
setting. In a 2007 study, the crude prevalence rate of stroke
in urban Nigeria was 1.14/1,000, lower than the rates in most
developed countries.38 In rural Nigeria, the crude prevalence
of stroke was 1.63/1,000.39 For comparison, the prevalence
of stroke among adult African Americans was 3.8% in
2012.40 The lower prevalence in Nigeria may be related to
lower incidence and higher stroke mortality compared with
developed countries.
Although descriptive data are limited, patients with stroke
in Africa are younger and have higher mortality than in other
regions. In a single-center study of stroke patients in Ethiopia,
the mean age of patients was 53.2 years and overall mortality
was 44.5%.41 In this study, hypertension was the most frequent
risk factor for stroke, followed by cardiac disease, observed
in 66% and 23% of patients, respectively. Hypertension was
undertreated, with most hypertensive patients receiving either
no treatment (29%) or erratic and irregular treatments (38%).
In another study from Kenya, the mean age for patients with
stroke was 61 years, and hypertension was found in 64%.42
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Valvular heart disease accounted for 40% of all heart disease,
and almost half the patients with VHD also had AF, of whom
none were on treatment.

Treatment options for AF management
Long-term anticoagulation is recommended to reduce the risk
of stroke in patients with AF.34,36,43,44 The vitamin K antagonists (VKAs), including warfarin, are well-studied, having
been used for many years, and low-cost generic versions are
readily available. Warfarin is effective at reducing stroke risk
in patients with AF, provided that good anticoagulation control is achieved by maintaining the international normalized
ratio (INR) in the therapeutic range for at least 60%–70% of
the time.45,46 A meta-analysis of six placebo-controlled trials
showed that warfarin significantly reduced stroke risk by 64%
and mortality by 26%.47 Use of warfarin, as in the case of all
anticoagulants, carries some risk of bleeding. Administration
of vitamin K can substantially reduce the effect of warfarin
on INR in 24 hours, but because warfarin has a much longer
duration of action than vitamin K, vitamin K may need
to be readministered in patients with ongoing bleeding.48
Alternatively, the effect of warfarin can be reversed more
rapidly by administering fresh frozen plasma.49 Warfarin
has a number of other limitations, including its slow onset
and offset of action, food and drug interactions that require
patients to be consistent in their dietary and alcohol intake,
and a narrow therapeutic range that requires regular INR
monitoring and dose adjustment to maintain anticoagulant
levels within the therapeutic range.50
While warfarin remains the most commonly used oral
anticoagulant in patients with AF, several non-vitamin K
antagonist oral anticoagulants (NOACs), including dabigatran, rivaroxaban, apixaban, and edoxaban, have recently
been approved to reduce the risk of stroke in patients with
NVAF.51–54 Potential advantages of the NOACs relative to
warfarin could be that they do not require routine INR or
other anticoagulant level monitoring, they do not have food
or drug interactions, and they can be prescribed in fixed
doses. Disadvantages of the NOACs compared with warfarin
include their cost and the current lack of a specific antidote.
Furthermore, they are not indicated for stroke prevention
in patients with valvular AF. The efficacy of these agents to
reduce the risk of stroke in NVAF has been demonstrated in
Phase III trials (Table 2).
In the RE-LY trial, patients with NVAF at moderate-tohigh risk of stroke were randomized to dabigatran (150 mg
twice daily [bid] or 110 mg bid) or open-label warfarin.
Both doses of dabigatran were noninferior to warfarin at
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Randomized, openlabel, rater-blinded,
noninferiority trial
RR: 0.65 (95% CI:
0.52, 0.81); P,0.001*,**
RR: 0.26 (95% CI:
0.14, 0.49); P,0.001
RR: 0.41 (95% CI:
0.28, 0.60); P,0.001
RR: 1.27 (95% CI:
0.94, 1.71); P=0.12
RR: 0.88 (95% CI:
0.77, 1.00); P=0.051
RR: 0.93 (95% CI:
0.81, 1.07); P=0.32

Warfarin

Warfarin

Randomized, openlabel, rater-blinded,
noninferiority trial
RR: 0.91 (95% CI:
0.74, 1.11); P=0.34*
RR: 0.31 (95% CI:
0.17, 0.56); P,0.001
RR: 0.30 (95% CI:
0.19, 0.45); P,0.001
RR: 1.29 (95% CI:
0.96, 1.75); P=0.09
RR: 0.91 (95% CI:
0.80, 1.03); P=0.13
RR: 0.80 (95% CI:
0.70, 0.93); P=0.003

RE-LY (dabigatran
150 mg)55

RE-LY (dabigatran
110 mg)55
Randomized, doubledummy, double-blind,
noninferiority trial
HR: 0.88 (95% CI: 0.75,
1.03); P=0.12a,*
HR: 0.59 (95% CI: 0.37,
0.93);c P=0.024
HR: 0.67 (95% CI: 0.47,
0.93);c P=0.02
HR: 0.81 (95% CI 0.63,
1.06);c P=0.121
HR: 0.92 (95% CI: 0.82,
1.03); P=0.15
HR: 1.04 (95% CI: 0.90,
1.20);c P=0.58

Warfarin

ROCKET AF
(rivaroxaban 20 mg)86
Randomized, doubledummy, double-blind,
noninferiority trial
HR: 0.79 (95% CI:
0.66, 0.95); P=0.01*
HR: 0.51 (95% CI:
0.35, 0.75); P,0.001
HR: 0.42 (95% CI:
0.30, 0.58);c P,0.001
HR: 0.88 (95% CI:
0.66, 1.17); P=0.37
HR: 0.89 (95% CI:
0.80, 0.998); P=0.047
HR: 0.69 (95% CI:
0.60, 0.80);c P,0.001

Warfarin

ARISTOTLE
(apixaban 5 mg)56
Randomized, doubledummy, double-blind,
superiority trial
HR: 0.45 (95% CI:
0.32, 0.62); P,0.001**
HR: 0.67 (95% CI:
0.24, 1.88); P=0.45
HR: 0.69 (95% CI:
0.38, 1.90); P=0.69
HR: 0.86 (95% CI:
0.50, 1.48); P=0.59
HR: 0.79 (0.62, 1.02);
P=0.07
HR: 1.13 (95% CI:
0.74, 1.75); P=0.57

Aspirin

AVERROES
(apixaban 5 mg)57

Randomized, doubledummy, double-blind,
noninferiority trial
HR: 0.79 (97.5% CI: 0.63,
0.99);b P,0.001*
HR: 0.54 (95% CI: 0.38,
0.77); P,0.001
HR: 0.47 (95% CI: 0.34,
0.63);c P,0.001
HR: 0.94 (95% CI: 0.74,
1.19); P=0.60
HR: 0.92 (95% CI: 0.83,
1.01); P=0.08
HR: 0.80 (95% CI: 0.71,
0.91);c P,0.001

Warfarin

ENGAGE AF-TIMI 48
(edoxaban 60 mg)58

Randomized, doubledummy, double-blind,
noninferiority trial
HR: 1.07 (97.5% CI: 0.87,
1.31);b P=0.005*
HR: 0.33 (95% CI: 0.22,
0.50); P,0.001
HR: 0.30 (95% CI: 0.21,
0.43);c P,0.001
HR: 1.19 (95% CI: 0.95,
1.49); P=0.13
HR: 0.87 (95% CI: 0.79,
0.96); P=0.006
HR: 0.47 (95% CI: 0.41,
0.55);c P,0.001

Warfarin

ENGAGE AF-TIMI 48
(edoxaban 30 mg)58

Notes: All values are for the intention-to-treat populations unless otherwise stated. *Noninferior to comparator; **superior to comparator; athe primary end point for ROCKET-AF used the per-protocol population. In the per-protocol
analysis, the HR for stroke or systemic embolism with rivaroxaban vs warfarin was 0.79 (95% CI: 0.66, 0.96; P,0.001 for noninferiority); bmodified intention-to-treat population in the treatment period; csafety on-treatment population.
Abbreviations: CI, confidence interval; HR, hazard ratio; NOAC, non-vitamin K antagonist oral anticoagulants; RR, relative risk; RE-LY AF, Randomized Evaluation of Long-Term Anticoagulation Therapy ROCKET-AF, Rivaroxaban Once
Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; ARISTOTLE, Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial
Fibrillation; AVERROES, Apixaban Versus Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment; ENGAGE AF-TIMI, Effective Anticoagulation
with Factor Xa Next Generation in Atrial Fibrillation -Thrombolysis in Myocardial Infarction.

Major bleeding

Stroke or systemic
embolism
Hemorrhagic
stroke
Intracranial
hemorrhage
Myocardial
infarction
All-cause mortality

Trial design

Comparator

Table 2 Phase III clinical trial results for the NOACs
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reducing stroke rates. Dabigatran 150 mg, but not 110 mg,
was superior to warfarin. Rates of hemorrhagic stroke were
significantly lower in both dabigatran arms than in the warfarin arm. Major bleeding occurred significantly less frequently
in the 110 mg dabigatran group and at similar rates in the
warfarin and dabigatran 150 mg groups.55
In the Rivaroxaban Once Daily Oral Direct Factor Xa
Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation
(ROCKET AF) trial, rivaroxaban was noninferior to warfarin
for prevention of stroke and systemic embolism in patients
with NVAF. There were no significant differences in the rates
of major, as well as clinically relevant nonmajor, bleeding
in patients taking rivaroxaban and warfarin. Intracranial
hemorrhage and fatal bleeding occurred significantly less
frequently with rivaroxaban, whereas gastrointestinal bleeding, bleeding that led to a drop in the hemoglobin level, and
bleeding that required transfusion occurred more frequently
with rivaroxaban.
In the Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, which included patients with NVAF and at least
one additional risk factor for stroke, apixaban 5 mg bid
(2.5 mg bid in selected patients) significantly reduced the
risk of stroke or systemic embolism, major bleeding, and
mortality compared with warfarin (target INR: 2–3).56 In
the Apixaban Versus Acetylsalicylic Acid [ASA] to Prevent
Stroke in Atrial Fibrillation Patients Who Have Failed or
Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial, apixaban 5.0 mg bid (2.5 mg bid in selected
patients) provided significantly more protection from stroke
and systemic embolism than aspirin 81–324 mg/day in
patients with NVAF at increased risk of stroke, without
significantly increasing major bleeding.57
In the Effective Anticoagulation with Factor Xa Next
Generation in Atrial Fibrillation -Thrombolysis in Myocardial
Infarction 48 (ENGAGE AF-TIMI 48) trial, patients with
NVAF were randomized to edoxaban 60 mg daily, edoxaban
30 mg daily, or warfarin (target INR: 2–3). Both once-daily
regimens of edoxaban were noninferior to warfarin with
respect to the prevention of stroke or systemic embolism,
as well as being associated with significantly lower rates of
bleeding and death from cardiovascular causes.58
Notably, a significant limitation of all the NOAC trials
with regard to the use of these drugs in the African population
is that none of the trials included a large number of patients
from Africa, and the percentage of black subjects overall
was small. Thus, the use of these newer agents compared
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with warfarin has not been well validated among subjects
from the African continent. Furthermore, the percentage of
patients with valvular (rheumatic) AF vs NVAF is expected
to be higher in Africa than in some other regions of the world.
The NOACs are not indicated in patients with significant
VHD (including hemodynamically significant/severe mitral
regurgitation or moderate-to-severe mitral or aortic valve
stenosis) or in patients with prosthetic heart valves.
As noted earlier, an important drawback of warfarin is
that patients require routine monitoring and dose adjustment
to maintain serum levels in the therapeutic range.50 Access to
monitoring may present a significant burden in some regions
of Africa due to remote geographic locations or limited
resources. Therefore, treatment with NOACs could minimize
logistical hurdles for patients who lack access to laboratory
services, as these drugs do not require routine monitoring;
in the authors’ experience, people in remote areas opt to use
NOACs instead of warfarin for this reason.
While the NOACs are widely available in Europe and the
US, the approval status of these agents varies in the countries
of Sub-Saharan Africa. The first NOAC approved for treatment of NVAF in Africa was dabigatran, which received
regulatory approval in Namibia in 2011.59 As of August 2014,
rivaroxaban and dabigatran have been approved in Kenya;60
rivaroxaban was the only NOAC approved in South Africa61
and Nigeria;62 and none of the NOACs were available in
Uganda63 or Zimbabwe.64 Up-to-date information about drug
approvals in many countries in the Sub-Saharan region is
difficult to obtain, and approvals are continuing; therefore,
the list above may be incomplete.

AF stroke prevention treatment
guidelines
Evidence-based guidelines published by national or regional
medical associations provide physicians with recommendations on how to manage patients with NVAF (Table 3).
The South African Stroke Society guidelines recommend
primary stroke prevention for patients with AF stratified by
CHADS2 risk score. Under these guidelines, patients with a
CHADS2 score of zero may be treated with aspirin; for those
with a CHADS2 score of one, warfarin or aspirin may be
appropriate; and those with a CHADS2 score of $2 should
receive warfarin.65 In addition to the CHADS2 score, physicians should consider patient preference, bleeding risk, and
access to reliable INR monitoring when making treatment
decisions.
The ESC guidelines use the CHA2DS2–VASc score to
predict stroke risk; the ESC recommends no treatment for
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Table 3 Guideline recommendations on the use of antithrombotic therapy for the prevention of stroke in patients with nonvalvular
atrial fibrillation, based on stroke risk
Guideline

CHADS2 risk score
0

1

$2

South African
Stroke Society (2010)

Aspirin alone

ACCP (2012)

No antithrombotic
therapy or aspirin
alone

Warfarin or aspirin, taking into account
patient preferences, bleeding risk, and
access to reliable INR monitoring
OAC suggested rather than no therapy
or aspirin/aspirin + clopidogrel
If OAC unsuitable or not desired,
aspirin + clopidogrel suggested rather
than aspirin alone

Warfarin recommended, taking into
account patient preferences, bleeding risk,
and access to reliable INR monitoring
OAC suggested rather than no therapy or
aspirin/aspirin + clopidogrel
If OAC unsuitable or not desired, aspirin +
clopidogrel suggested rather than aspirin
alone

Guideline

CHA2DS2–VASc risk score
0

1

$2

ESC (2012)

No antithrombotic
therapy

NICE (2014)

No OAC
recommended

ACC/AHA/HRS
(2014)
ASA/AHA
(2014)

Reasonable to omit
antithrombotic therapy
Reasonable to omit
antithrombotic therapy

Consider OAC, depending on individual
risk (not recommended in female
patients aged ,65 years with lone AF)
Consider OAC for men, taking into
account bleeding risk and individual
patient risks and preferences
Either no therapy or consider aspirin
or OAC
No antithrombotic therapy,
anticoagulant therapy, or aspirin
therapy may be considered

NOAC (dabigatran, rivaroxaban, and
apixaban) or VKA recommended. If patient
refuses OAC, consider aspirin + clopidogrel
OAC recommended, taking into account
bleeding risk and individual patient risks and
preferences
OAC recommended, either warfarin
(INR 2–3) or NOAC
OAC recommended, either warfarin
(INR 2–3) or NOAC

Abbreviations: ACC/AHA/HRS, American College of Cardiology/American Heart Association/Heart Rhythm Society; ACCP, American College of Chest Physicians;
AF, atrial fibrillation; ASA, American Stroke Association; CHADS2, Congestive heart failure, Hypertension, Age $75 years, Diabetes (one point each), Stroke or transient
ischemic attack (two points); ESC, European Society of Cardiology; INR, international normalized ratio; NICE, National Institute for Health and Care Excellence;
NOAC, non-vitamin K antagonist oral anticoagulants; OAC, oral anticoagulant; VKA, vitamin K antagonist.

patients at low risk (CHA2DS2–VASc score of zero) and
VKA or NOAC therapy for those at moderate-to-high risk
(CHA2DS2–VASc score $1). In contrast to the South African
guidelines, aspirin is recommended only for patients who
refuse oral anticoagulant therapy.43
The National Institute for Health and Care Excellence
(NICE) in the United Kingdom also stratifies patients by the
CHA2DS2–VASc score. NICE advises that anticoagulation
may be established with apixaban, dabigatran, rivaroxaban,
or a VKA and recommends considering anticoagulation
for men with a CHA2DS2–VASc score of one and offering
anticoagulation to men and women with a CHA2DS2–VASc
score $2. Bleeding risk should be taken into account, and
the choice of anticoagulant should be based on the clinical
features and preferences of the patient.66
In the absence of regional guidelines, physicians in
Africa also have the option of referring to any of several different treatment guidelines published by US-based medical
societies. The AHA and the American Stroke Association
Scientific Advisory use the CHA2DS2–VASc score and recommend that it is reasonable to omit antithrombotic therapy
for patients with a CHA2DS2–VASc score of zero; no antithrombotic therapy, anticoagulant therapy, or aspirin therapy
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may be considered for patients with a CHA2DS2–VASc score
of one; and oral anticoagulants are recommended for patients
with a CHA2DS2–VASc score $2. Options include warfarin
(INR: 2.0–3.0), dabigatran, apixaban, and rivaroxaban.67 The
American College of Chest Physicians advises no therapy
for patients with a CHADS2 score of zero and oral anticoagulants for patients with CHADS2 score $1, with aspirin/
clopidogrel as an alternative for patients for whom oral
anticoagulants are not appropriate.44 The ACC/AHA/HRS
guidelines state that it is reasonable to omit antithrombotic
therapy for patients with a CHA2DS2–VASc score of zero
and suggest an oral anticoagulant or aspirin for patients
with a CHA2DS2–VASc score of one. Oral anticoagulants
(either warfarin or NOACs) are preferred for patients with
CHA2DS2–VASc scores $2.36

Costs of AF and stroke
As in the rest of the world, both the costs associated with
AF treatment and the costs of untreated AF are significant
concerns in Africa. Indeed, given the paucity of resources
available to much of the population of Africa, cost-effective
management of AF is of paramount importance. Costs
associated with AF may be related to anticoagulant therapy,
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INR monitoring, or treatment of AF-related stroke. Failure
to maintain optimal anticoagulation places patients at risk
of complications, including both stroke and bleeding, the
management of which involves a significant cost.68 A chart
review of stroke patients in Nigeria revealed that patients
require an average of US$600 and $4,860 (direct costs only)
in a government and a private hospital, respectively, to access
care within the first 36 weeks poststroke.69 Average income in
Nigeria is ,$2/day, which suggests that managing stroke constitutes a huge direct cost burden unaffordable by an average
Nigerian stroke sufferer.69 Cost-effectiveness studies for the
region are limited; however, one study in the South African
private sector indicated that compared with warfarin, dabigatran as first-line treatment was cost effective in reducing the
risk of stroke in patients with AF when used in accordance
with its registered indication. While the costs of dabigatran
were estimated to be higher than those for warfarin (Rands
[R] 60,365 vs R24,243, respectively), the costs of clinical
events and follow-up costs were estimated to be lower than for
warfarin (R23,246 vs R24,888 and R236,496 vs R252,229,
respectively).70
Although NOACs are available in certain parts of Africa,
the drug costs of the NOACs make them unaffordable for
many patients. Because generic warfarin is available at
lower cost, warfarin and other VKAs are likely to remain
the standard of care in the region.71 Notably, however, as
prosperity in Africa (measured as the proportion of the
population living above the poverty line) increases,72 the
African middle class may find the convenience of NOACs,
with their reduced burden of monitoring and fewer food–
drug interactions, preferable to warfarin irrespective of their
drug-related costs.

Real-world treatment with anticoagulants
for stroke prevention
Several studies have demonstrated wide variability in the use
of anticoagulant therapy in clinical practice in Africa, probably related to regional differences in access to medical care
across the African continent. In general, treatment patterns
differ between rural and urban settings, with urban patients
more likely to receive anticoagulants. One study noted that
urban patients were more likely to have a relative contraindication to antithrombotic therapy than rural patients (24% vs
10%; P=0.028) but received antithrombotic therapy more
often (38% vs 19%; P=0.025).73 In a prospective study of
AF patients in Cameroon between 2006 and 2007, in patients
with an indication for oral anticoagulation, only 34% (54 of
158) actually received it.15 Similarly, in a hospital-based
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study from Soweto, South Africa, between 2006 and 2008,
33% of patients with AF received warfarin.2 In contrast,
a much higher percentage of patients received an anticoagulant in Senegal, where in a retrospective hospital-based
study between 2003 and 2007, anticoagulation by VKA was
established in 62% of cases.18 Access to quality health care
may be getting better in some parts of Africa with improving
economic and social conditions. A study at a private urban
referral teaching hospital in Nairobi, Kenya, found that
80% of patients with AF and a CHADS2 score $2 received
anticoagulation between 2008 and 2010.19 Similarly, a recent
observational multicenter national registry in South Africa
indicated that 75% of patients with AF were on warfarin for
stroke prevention in 2010 and 2011.74
Among patients who receive anticoagulant therapy, INR
control varies greatly. In a post hoc analysis of Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of
Vascular Events -Warfarin arm (ACTIVE-W), a randomized
prospective trial comparing VKA therapy with clopidogrel
plus aspirin, patients from South Africa randomized to
VKA therapy (n=98) achieved poor INR control, with the
lowest time in therapeutic range (TTR) of any country in
the trial.45,75 Patients from South Africa had a mean TTR
of 46%, vs 63% for the study population as a whole.45 In
contrast, in ROCKET-AF, the median individual TTR for
South African patients on warfarin was similar to that of
the study population as a whole (55% for each group).76 In
ARISTOTLE, the median TTR for patients on warfarin was
approximately 68% for patients in South Africa, vs a median
of 66% (52%–77%) for the study population as a whole.77
However, TTR for patients enrolled in randomized controlled
clinical trials may not provide an accurate reflection of TTR
for patients treated in clinical practice. Among the regions
enrolled in the RE-LY AF registry, TTR was lower in Africa
than in Europe or North America.37 In a multicenter study
in South Africa, although all the patients were maintained
above the minimum INR value of 2.0, approximately 50%
had at least one record of INR above the cut-off value of 3.5,
possibly reflecting barriers of cost and access that may be
especially problematic for rural patients.78
Observational studies have begun assessing the impact,
safety, and efficacy of the NOACs for stroke prevention in
AF in routine clinical practice around the world. It will be of
interest to understand how these novel treatments are being
used in the real-world clinical setting. Global Registry on
Long-Term Oral Antithrombotic Treatment in Patients with
Atrial Fibrillation (GLORIA-AF) is a large multinational
prospective registry designed to characterize the treatment
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of patients newly diagnosed with NVAF who are at risk of
stroke and who are being treated with warfarin, aspirin, and
NOACs; GLORIA-AF should provide important real-world
information on antithrombotic-prescribing patterns and
patient outcomes. It is vital to analyze whether the safetyand-efficacy profile of NOACs established in the clinical trials
is also observed in routine clinical practice. In this regard,
Xarelto® (Janssen Pharmaceuticals, Inc., Titusville, NJ,
USA) for Prevention of Stroke in Patients with Nonvalvular
Atrial Fibrillation, Eastern Europe, Middle East, Africa, and
Latin America (XANTUS-EL) is evaluating rivaroxaban.
GLORIA-AF and XANTUS-EL will include South African
and Kenyan sites, respectively. Similarly, the ongoing Global
Anticoagulant Registry in the FIELD-Atrial Fibrillation
(GARFIELD-AF) international observational prospective
study aims to investigate real-life treatment patterns and
patient outcomes, and it includes South African sites.79,80

Rate control vs rhythm control in AF
Although stroke prevention is a critically important therapeutic goal in AF patients, management of AF patients is also
aimed at reducing symptoms and preventing other complications associated with AF by control of the ventricular rate and
correction of the rhythm disturbance. Rate control appears
to be the preferred treatment strategy relative to rhythm
control for AF management among most clinicians treating
patients with AF in Africa. At a private referral hospital in
Nairobi, rate control, using a mixture of digoxin, betablockers, calcium channel blockers, and amiodarone, alone
and in combination, was the preferred strategy for arrhythmia
management in 78% of patients.19 A national observational
registry in South Africa found that rate control, mainly
with beta-blockers, was pursued in 64% of AF patients.74
A prospective study involving ten cardiologists in Cameroon
treating AF found that a rate control strategy using digoxin
and amiodarone was chosen in 84% of patients.15 Consistent
with these observations, a study that assessed pharmacological management of AF in developing countries around the
world found a high prevalence of rate control therapy use
(55%–87%).16 This treatment approach contrasts with AF
management in developed countries, where physicians generally prefer rhythm control over rate control strategies. The
REgistry on Cardiac rhythm disORDers assessing the control
of Atrial Fibrillation (RecordAF) observational study of AF
management among recently diagnosed patients in Europe,
America, and Asia reported that rhythm control was applied
to 55% of patients, whereas rate control was selected in 45%
of patients at baseline.81 Similarly, in the Euro Heart Survey,
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67% of symptomatic patients with AF were managed with a
rhythm control approach.28

Barriers to evidence-based health care in patients
with AF
While the provision of good health care at low cost is an
extremely complex undertaking, countries such as Ethiopia
have substantially improved their health care systems in
recent years, and their success points to factors that may
affect the ability of other countries to improve.82 Factors
that influenced success included political commitment,
effective bureaucracies, and the ability to innovate and adapt
to resource limitations.82
In Sub-Saharan Africa, the leading cardiovascular cause
of death and disability is stroke, and cardiovascular deaths
occur at younger ages than in the rest of the world.7 Rates
of stroke-related disability and mortality are ten fold higher
in medically underserved regions of the world compared
with the most developed nations.83 This is primarily due to
the lack of access to primary care to screen for and mitigate
stroke risk factors.83 In the developed world, AF is the leading preventable cause of stroke, accounting for 15%–20%
of all strokes.84 Therefore, effective strategies to reduce the
risk of stroke in patients with AF must be considered in the
context of local health care systems.
A recent proof-of-concept study in Ethiopia and
Swaziland adapted tools and systems originally developed for
long-term routine care of patients with HIV to treat patients
with noncommunicable diseases using diabetes mellitus,
another condition requiring ongoing monitoring and care,
as a test case.85 The study demonstrated the potential to
rapidly improve the quality of care for diabetes by adapting
HIV-specific policies, systems, and tools.85 This approach
could potentially be expanded to other noncommunicable
conditions, such as AF.

Summary and conclusion
Although infectious disease has historically been a greater
health concern in Africa, noncommunicable disease, including
AF and stroke, is a growing issue in a setting where resources
and access to health care are extremely limited for a large
portion of the population. Data on epidemiology of AF in
Africa are scarce. The available information suggests a lower
prevalence of diagnosed AF currently in Sub-Saharan Africa,
but the prevalence of AF in this region is expected to grow
significantly over the next 2–3 decades. When AF is detected
in Africa, it is more likely to be permanent and associated with
high morbidity and mortality. Patients with AF in Africa are
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much more likely to be treated with rate control rather than
rhythm control in comparison with patients in Europe or the
US. Valvular AF is much more common in Africa than in
Europe or the US due to the high burden of rheumatic heart
disease. Warfarin or the NOACs are treatment options for
stroke prevention in NVAF, whereas the NOACs are not indicated for treatment of valvular AF. While undertreatment of
AF remains a worldwide problem, patients with AF in Africa
are even more likely to be undertreated than those in other
regions due to major differences in the availability of health
care resources and socioeconomic conditions. In most of
Africa, fewer patients with AF receive anticoagulant therapy
compared with those in other parts of the world. In addition,
some studies suggest that those receiving treatment may have
shorter times in the therapeutic range while receiving warfarin.
Although the overall prevalence of stroke in Africa is low
compared with that in the developed world, possibly due to
the younger age of the region’s population, AF is a leading
preventable cause of stroke. Undertreatment of AF patients
with antithrombotic therapy leaves patients at increased risk
of stroke. Furthermore, morbidity and mortality associated
with AF-related stroke is significant. NOACs are starting to
become available around Africa, and as availability increases,
health care providers in Africa will have new treatment
options to manage NVAF and reduce the risk of stroke in their
patients. More studies and resources are needed to improve
understanding of the epidemiology and management of AF
in Sub-Saharan Africa.
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